Jason Zemansky
Stock Analyst at B of A Securities
(3.91)
# 641
Out of 5,030 analysts
43
Total ratings
83.33%
Success rate
53.19%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jason Zemansky
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYTK Cytokinetics | Maintains: Neutral | $52 → $56 | $58.56 | -4.37% | 5 | Oct 2, 2025 | |
| HOWL Werewolf Therapeutics | Maintains: Buy | $9 → $8 | $1.61 | +396.89% | 5 | Aug 25, 2025 | |
| RCKT Rocket Pharmaceuticals | Upgrades: Buy | $4 → $10 | $3.69 | +171.00% | 2 | Aug 20, 2025 | |
| INSM Insmed | Maintains: Buy | $94 → $109 | $164.51 | -33.74% | 10 | Jun 11, 2025 | |
| KROS Keros Therapeutics | Downgrades: Neutral | $32 → $18 | $13.73 | +31.10% | 2 | Jun 10, 2025 | |
| TVTX Travere Therapeutics | Maintains: Buy | $29 → $31 | $27.51 | +12.69% | 4 | Apr 1, 2025 | |
| RCUS Arcus Biosciences | Maintains: Neutral | $22 → $17 | $16.29 | +4.36% | 5 | Feb 19, 2025 | |
| KURA Kura Oncology | Maintains: Buy | $36 → $29 | $9.82 | +195.32% | 2 | Nov 22, 2024 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $30 → $31 | $14.51 | +113.65% | 3 | Aug 15, 2024 | |
| ESPR Esperion Therapeutics | Downgrades: Underperform | $2.9 → $2.5 | $2.76 | -9.42% | 5 | Jun 20, 2024 |
Cytokinetics
Oct 2, 2025
Maintains: Neutral
Price Target: $52 → $56
Current: $58.56
Upside: -4.37%
Werewolf Therapeutics
Aug 25, 2025
Maintains: Buy
Price Target: $9 → $8
Current: $1.61
Upside: +396.89%
Rocket Pharmaceuticals
Aug 20, 2025
Upgrades: Buy
Price Target: $4 → $10
Current: $3.69
Upside: +171.00%
Insmed
Jun 11, 2025
Maintains: Buy
Price Target: $94 → $109
Current: $164.51
Upside: -33.74%
Keros Therapeutics
Jun 10, 2025
Downgrades: Neutral
Price Target: $32 → $18
Current: $13.73
Upside: +31.10%
Travere Therapeutics
Apr 1, 2025
Maintains: Buy
Price Target: $29 → $31
Current: $27.51
Upside: +12.69%
Arcus Biosciences
Feb 19, 2025
Maintains: Neutral
Price Target: $22 → $17
Current: $16.29
Upside: +4.36%
Kura Oncology
Nov 22, 2024
Maintains: Buy
Price Target: $36 → $29
Current: $9.82
Upside: +195.32%
Syndax Pharmaceuticals
Aug 15, 2024
Maintains: Buy
Price Target: $30 → $31
Current: $14.51
Upside: +113.65%
Esperion Therapeutics
Jun 20, 2024
Downgrades: Underperform
Price Target: $2.9 → $2.5
Current: $2.76
Upside: -9.42%